Formulations of 1% silver sulfadiazine in the treatment of burns
DOI:
https://doi.org/10.35954/SM2018.37.1.7Keywords:
Administration, Topical Skin Cream; Burns; Silver Sulfadiazine.Abstract
This work seeks to compile information on the use of pharmaceutical preparations for topical use containing the active ingredient Silver Sulfadiazine 1%. Its use is extended to different types of burns. In superficial burns (both first and second degree) the main objective is healing with the least scarring. In these wounds it is essential to achieve re-epithelialization. It is also important to keep the wounds moist to avoid scar formation. In deep burns, re-epithelialization does not occur and less scarring will occur if grafts are performed. Topical agents are currently applied during the short period between excision and then grafting. In pediatric patients, any hot fluid burn can generate significant injury because their skin is thinner. Although membranous dressings have a better response, in certain areas of the body it is easier to use topical agents. Regarding adverse effects, although there is not much information, silver may slow the healing process and may have cytotoxic activity on host cells. Renal toxicity has been reported with high concentrations of silver in blood and urine. Regarding associations with chlorhexidine, given the possibility that its presence may generate irritation in the area to be treated, we consider that priority should be given to the use of 1% Silver Sulfadiazine in cream only, without associating it with other active ingredients. If necessary, the wounds should be previously washed with chlorhexidine-based soap solution. In conclusion, this product can be used in different types of burns; it will be the job of the treating professional to choose when and how to administer it. It is important to consider that there have been described experiences of adverse reactions that should not be ignored at the time of indication.
Downloads
References
(1) Heyneman A, Hoeksema H, Vandekerckhove D, Pirayesh A, Monstrey S. The role of silver sulphadiazine in the conservative treatment of partial thickness burn wounds: A systematic review. Burns 2016; 42(7):1377-1386.
(2) Percival SL, Finnegan S, Donelli G, Vuotto C, Rimmer S, Lipsky BA. Antiseptics for treating infect-ed wounds: Efficacy on biofilms and effect of pH. Crit Rev Microbiol 2016; 42(2):293-309.
(3) Hernández R, Garibay M. Sulfadiazina de plata en crema versus suspensión tópica en quemaduras de segundo grado. Rev Mex Pediatr 2011; 78(2):56-60.
(4) Agencia Española de Medicamentos y Productos Sanitarios. Ficha técnica Nº 53324. Flammazine 10 mg/g crema. Disponible en: https://www.aemps.gob.es/cima/pdfs/es/ft/53324/FichaTecnica_53324.html.pdf [Consulta 28/09/17].
(5) Trejos N, Tello M. Validación de una metodo-logía analítica por HPLC para la cuantificación de sulfadiazina de plata en crema. Rev colomb cienc quim farm 2008; 37(2):191-99.
(6) Porras-Luque JI. Antimicrobianos tópicos en Derma-tología. Actas Dermosifiliogr 2007; 98 Suppl 1:29-39.
(7) Greenhalgh DG. Topical Antimicrobial Agents for BurnWounds. Clin Plast Surg 2009; 36(4):597-606.
(8) Atiyeh BS, Costagliola M, Hayek SN, Dibo SA. Ef-fect of silver on burn wound infection control and heal-ing: review of the literature. Burns 2007; 33(2):139-48.
(9) Vloemans AF, Hermans MH, van der Wal MB, Liebregts J, Middelkoop E. Optimal treatment of partial thickness burns in children: A systematic re-view. Burns 2014; 40(2):177-190.
Published
How to Cite
Issue
Section
License
Until 2024 we use the Creative Commons Attribution/NonCommercial Attribution 4.0 International License https://creativecommons.org/licenses/by-nc/4.0/deed.es. Which states that: you are free to share, copy and redistribute the material in any medium or format, as well as to adapt, remix, transform and build upon the material. Under the following terms:
Attribution: you must give proper credit , provide a link to the license, and indicate if changes have been made . You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
NonCommercial: you may not use the material for commercial purposes.
As of 2025 authors retain their copyright and assign to the journal the right of first publication of their work, which shall simultaneously be subject to the license https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es that permits sharing, copying and redistribution of the material in any medium or format provided that initial publication in this journal is indicated. Adapt, remix, transform and build upon the material. If you remix, transform, or build from the material, you must distribute your contribution under the same license as the original and may not make use of the material for commercial purposes.
Under the following terms:
1. Attribution: you must give proper credit, provide a link to the license, and indicate whether changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
2. NonCommercial: you may not use the material for commercial purposes.
3. ShareAlike: if you remix, transform or build upon the material, you must distribute your contribution under the same license as the original.
PlumX Metrics
